CYTK PDUFA decision: a positive outcome, +7.4%

On April 30, 2026, Omecamtiv Mecarbil — Cytokinetics, Incorporated (Heart Failure With Reduced Ejection Fraction) reached its PDUFA decision. The result was a positive outcome, and the stock moved +7.4% in the window around the event. It had already run -6.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.